% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • jfk123_1 jfk123_1 Aug 19, 2013 6:10 PM Flag

    UBS/Brean meetings with management mean.......

    Expect coverage initiation from UBS after the recent meeting with management. Brean meets tomorrow evening with management, so could see some action in shares/new research in the aftermath.

    UBS meeting is interesting. Kovner could be looking to take private with Coxton, although UBS could be courted so as to push through the 300m shelf registration later this year. In order to work the shelf registration to UBS's very wide distribution base, UBS would have to launch proper coverage first. This would of course be good for Synta, as it would bring in a bulge bracket investment bank and the associated clout and services. Synta would probably want to execute on some or all of the shelf off the back of a major rise in shares. So if UBS is brought in and launches coverage, expect them to slap a bullish recommendation with a high price target in line with Roth and Jefferies. This would let the shares run, get Synta the money it needs, and give UBS some decent comms and primary income.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.3430.000(0.00%)Jul 22 4:00 PMEDT